Clinical Trial Update: ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial [Phase 4]

View source ↗

Summary

Phase 4 randomized open-label trial evaluating switching HIV-1 patients taking Kivexa plus Kaletra to address cholesterol elevations. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Kaletra (lopinavir)
• Kivexa (abacavir/lamivudine)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 | Phase 4 | Status: COMPLETED